HAMAD MEDICAL CORPORATION
๐ถ๐ฆQatar
Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan
Not Applicable
Completed
- Conditions
- Hypothyroidism
- Interventions
- Other: timing of receiving the drug
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 106
- Registration Number
- NCT03988517
- Locations
- ๐ถ๐ฆ
Hamad General Hospital, Doha, Qatar
Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 220
- Registration Number
- NCT03846973
- Locations
- ๐ถ๐ฆ
Hamad General Hospital, Doha, Qatar
Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 648
- Registration Number
- NCT03794518
- Locations
- ๐ถ๐ฆ
Heart Hospital, Hamad Medical Coorporation, Doha, Qatar
Qatar Cardiovascular Biorepository of AF Patients
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT03660696
- Locations
- ๐ถ๐ฆ
Heart Hospital, Hamad Medical Coorporation, Doha, Qatar
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
Phase 3
- Conditions
- PreDiabetesMyocardial InfarctionT2DM (Type 2 Diabetes Mellitus)CVD
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 576
- Registration Number
- NCT03658031
- Locations
- ๐ถ๐ฆ
Heart Hospital, Hamad Medical Coorporation, Doha, Qatar
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
Phase 3
- Conditions
- Blood Transfusion, HomologousBlood DiseaseBlood Transfusion, AutologousBlood Doping
- Interventions
- Biological: Homologous Blood TransfusionBiological: Autologous Blood Transfusion
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03548766
- Locations
- ๐ถ๐ฆ
Hamad Medical Corporation, Doha, Qatar
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 210
- Registration Number
- NCT03523221
- Locations
- ๐ถ๐ฆ
Hamad Medical Corporation, Doha, Qatar
Clinical Trial Comparing Intravenous and Oral Diclofenac and Pharmacokinetics
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT03472339
- Locations
- ๐ถ๐ฆ
Isma Qureshi, Doha, Qatar
Oxidative Stress In Semen And Male Infertility
Phase 4
- Conditions
- Semen QualityAntioxidantsInfertility, Male
- Interventions
- Drug: Fairhaven Pro for menDiagnostic Test: Semen analysisDiagnostic Test: Sperm DNA fragmentationDiagnostic Test: Static Oxidation reduction potential in semen
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT03464656
- Locations
- ๐ถ๐ฆ
Hamad Medical Corporation, Doha, Qatar
A Biorepository for Coronary Heart Disease in Qatar
Completed
- Conditions
- Coronary Heart Disease (CHD)
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 2100
- Registration Number
- NCT03427489
- Locations
- ๐ถ๐ฆ
Hamad Medical Corporation, Doha, Qatar
ยฉ Copyright 2025. All Rights Reserved by MedPath